Spanish Health Ministry to Fund Generic Version of "Champix"

Regulations by 2FIRSTS.ai
May.30.2024
Spanish Health Ministry to Fund Generic Version of "Champix"
Spain's Health Ministry to fund generic version of "Champix" from June, after original version pulled due to impurities.

According to El Mundo on May 29th, the Spanish Ministry of Health will start funding generic versions of "Champix" from June, a drug that was previously removed from the market due to impurities found in the production process of its main component, Varenicline.

 

Susana Verdejo, director of the Tobacco Prevention and Control Department at the Spanish Ministry of Health, revealed during a World No Tobacco Day meeting on Wednesday (May 29) that the active ingredient varenicline in the pharmaceutical giant Pfizer's drug "Champix" was ordered to be removed from shelves in 2021 by the Spanish Agency of Medicines and Medical Devices (AEMPS) due to the presence of carcinogenic nitrosamine impurities above permitted levels during the manufacturing process. It is expected that in June, the version of the drug produced by the designated manufacturer Normon will be available for sale in Spanish pharmacies.

 

In Spain, two smoking cessation medications, "Todacitán" and "Recigarum," have received funding. Therefore, there are currently three smoking cessation medications available in Spain.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Kuwait Bans Sale of Tobacco and E-Cigarette Products Through Delivery Platforms
Kuwait Bans Sale of Tobacco and E-Cigarette Products Through Delivery Platforms
Kuwait’s Minister of Commerce and Industry Osama Boodai has issued a decision banning the sale of tobacco, tobacco derivatives, all types of cigarettes, electronic cigarettes, and related tools, devices and accessories through delivery platforms or similar digital channels.
Mar.16 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Nigeria’s House of Representatives Plans to Amend the National Tobacco Control Act to Close Regulatory Gaps on E-cigarettes and Other Emerging Nicotine Products
Nigeria’s House of Representatives Plans to Amend the National Tobacco Control Act to Close Regulatory Gaps on E-cigarettes and Other Emerging Nicotine Products
Nigeria’s House of Representatives said it will review the National Tobacco Control Act to address regulatory gaps around emerging nicotine products such as e-cigarettes and to strengthen border controls and enforcement coordination. A relevant committee visited the headquarters of the Nigeria Customs Service, stressing linkage and cooperation among the NDLEA, NAFDAC and Customs.
Feb.26 by 2FIRSTS.ai
Multi-agency crackdown targets vape and convenience stores across Wirral, seizing illegal cigarettes and non-compliant pods
Multi-agency crackdown targets vape and convenience stores across Wirral, seizing illegal cigarettes and non-compliant pods
A multi-agency, intelligence-led enforcement operation took place on January 27, 2026, targeting vape and convenience stores across Wirral, including West Kirby, to disrupt the supply of illegal tobacco and vaping products. Six premises were inspected, with approximately 10,500 illegal cigarettes seized along with vape pods that were not in original packaging or did not meet UK regulatory requirements.
Feb.05 by 2FIRSTS.ai
Glasgow bin lorry fires spark calls to broaden vape and battery disposal messaging
Glasgow bin lorry fires spark calls to broaden vape and battery disposal messaging
Glasgow residents have been warned that throwing batteries and vapes away at home can endanger refuse workers, amid bin lorries catching fire. The city council said it will launch a communications campaign next month to tell people to place batteries in special bins at supermarkets or household waste recycling centres, supported by a dedicated web page listing other disposal sites.
Feb.11 by 2FIRSTS.ai
China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Announces FY2025 Results: Revenue Reaches HK$14.58 Billion, Up 11.5% Year-on-Year
China Tobacco International (HK) Company Limited announced its audited results for the year ended December 31, 2025. Revenue was HK$14.58 billion, profit before taxation was HK$1.28 billion, and profit attributable to owners of the Company was HK$0.98 billion, with basic and diluted EPS of HK$1.42. The Board proposed a final dividend of HK$0.33 per share; together with an interim dividend of HK$0.19 per share, the full-year dividend totaled HK$0.52 per share.
Mar.06 by 2FIRSTS.ai